Anti-Ku antibody-positive scleroderma-dermatomyositis overlap syndrome developing Graves' disease and immune thrombocytopenic purpura.

Intern Med

Department of Molecular and Internal Medicine, Division of Clinical Medical Science, Programs for Applied Biomedicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima.

Published: December 2002

Graves' disease (GD) has been reported to be frequently complicated with other autoimmune diseases. However, it is rarely complicated with scleroderma-polymyositis overlap syndrome. Recently, we encountered a 35-year-old woman who developed GD and immune thrombocytopenic purpura during follow-up observation of scleroderma-dermatomyositis overlap syndrome. Platelet counts recovered after high-dose gamma-globulin therapy and bolus methylprednisolone therapy. The present case is the first report of a combination of scleroderma, dermatomyositis, GD, and immune thrombocytopenic purpura. The patient was anti-Ku antibody-positive and had relatively low natural killer T cell counts, both of which might contribute to the complication of multiple autoimmune diseases.

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.41.1199DOI Listing

Publication Analysis

Top Keywords

overlap syndrome
12
immune thrombocytopenic
12
thrombocytopenic purpura
12
anti-ku antibody-positive
8
scleroderma-dermatomyositis overlap
8
graves' disease
8
autoimmune diseases
8
antibody-positive scleroderma-dermatomyositis
4
syndrome developing
4
developing graves'
4

Similar Publications

Introduction: The COVID-19 pandemic had a widespread global impact and presented numerous challenges. The emergence of SARS-CoV-2 variants has changed transmission rates and immune evasion, possibly impacting the severity. This study aims to investigate the impact of variants on clinical outcomes in southern Brazil.

View Article and Find Full Text PDF

Miller-Fisher syndrome (MFS) is characterized by the three major components of ophthalmoplegia, ataxia, and areflexia. The occurrence of MFS is relatively uncommon because of its monophasic nature, while recurrent Guillain-Barré syndrome (GBS) is a well-known condition. The pharyngeal-cervical-brachial (PCB) variant is a scarce variant of GBS (3%), which presents with muscle weakness initially involving the neck, oropharynx, and upper extremities.

View Article and Find Full Text PDF

Sepsis Diagnosis Based on a Parylene Matrix Chip Using LPC16:0 as a Biomarker in Comparison with Colorimetry of Total Phospholipid.

ACS Appl Bio Mater

January 2025

Department of Materials Science and Engineering, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul 03722, South Korea.

For the medical diagnosis of sepsis, it is crucial to differentiate infectious inflammation from noninfectious symptoms to prevent acute aggravation. Herein, a diagnosis for early stage sepsis was performed using LPC 16:0 and total phospholipids as small molecular biomarkers. The measurement of LPC 16:0 was conducted using a parylene matrix chip, which was developed to effectively detect small molecules in laser desorption/ionization mass spectrometry (LDI-MS).

View Article and Find Full Text PDF

The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity.

View Article and Find Full Text PDF

Post-COVID-19 Condition and Pulmonary Embolism.

J Multidiscip Healthc

December 2024

Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

Purpose: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes post-acute sequelae of coronavirus disease 2019 (COVID-19), including pulmonary vasculopathy, increasing thrombotic risk. Screening and treating survivors are essential to reduce associated disabilities. We aim to investigate the clinical characteristics of patients with post-COVID-19 condition and pulmonary embolism, as well as their health-related quality of life one year after COVID-19 diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!